Prostate Power Play: Does Accelerate -Deficient Cancer Progression?

PI3K pathway alterations are frequently recurrent in metastatic prostate cancer and are associated with the development of currently incurable castration-resistant disease. Candidate inhibitors that target single PI3K pathway members lack efficacy as demonstrated in multiple clinical trials. In this issue, Pearson and colleagues examine the functional importance of co-occurring and aberrations using a novel mouse model and demonstrate a synergistic acceleration of tumorigenesis that may be responsible for metastatic prostate cancer. .